Table of Contents

1 Global Market Overview

• 1.1 Scope of Statistics
  • 1.1.1 Scope of Products
  • 1.1.2 Scope of Manufacturers
  • 1.1.3 Scope of Application
  • 1.1.4 Scope of Type
  • 1.1.5 Scope of Regions/Countries
• 1.2 Global Market Size

2 Regional Market

• 2.1 Regional Production
• 2.2 Regional Demand
• 2.3 Regional Trade

3 Key Manufacturers

• 3.1 Bristol-Myers Squibb(BMS)
  • 3.1.1 Company Information
  • 3.1.2 Product & Services
  • 3.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.1.4 Recent Development
• 3.2 Merck
  • 3.2.1 Company Information
  • 3.2.2 Product & Services
  • 3.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 3.3 Roche
  • 3.3.1 Company Information
  • 3.3.2 Product & Services
  • 3.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

4 Major Application

• 4.1 Melanoma treatment
  • 4.1.1 Overview
  • 4.1.2 Melanoma treatment Market Size and Forecast
• 4.2 Bladder cancer treatment
  • 4.2.1 Overview
  • 4.2.2 Bladder cancer treatment Market Size and Forecast
• 4.3 Others
  • 4.3.1 Overview
  • 4.3.2 Others Market Size and Forecast

5 Market by Type

5.By PD-1 inhibitors

• 5.1 PD-1 inhibitors
  • 5.1.1 Overview
  • 5.1.2 PD-1 inhibitors Market Size and Forecast
• 5.2 PD-L1 inhibitors
  • 5.2.1 Overview
  • 5.2.2 PD-L1 inhibitors Market Size and Forecast
• 5.3 CTLA-4 inhibitors
  • 5.3.1 Overview
  • 5.3.2 CTLA-4 inhibitors Market Size and Forecast

6 Price Overview

• 6.1 Price by Manufacturers
• 6.2 Price by Application
• 6.3 Price by Type

7 Conclusion

Summary
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
The global Checkpoint Inhibitors for Treating Cancer market will reach xxx Million USD in 2019 with CAGR xx% 2019-2025. The main contents of the report including:
Global market size and forecast
Regional market size, production data and export & import
Key manufacturers profile, products & services, sales data of business
Global market size by Major Application
Global market size by Major Type
Key manufacturers are included based on company profile, sales data and product specifications etc.:
Bristol-Myers Squibb(BMS)
Merck
Roche
Major applications as follows:
Melanoma treatment
Bladder cancer treatment
Others
Major Type as follows:
PD-1 inhibitors
PD-L1 inhibitors
CTLA-4 inhibitors
Regional market size, production data and export & import:
Asia-Pacific
North America
Europe
South America
Middle East & Africa